Background-Prior studies suggest differences in stroke care associated with race/ethnicity. We sought to determine whether such differences existed in a population of black, Hispanic, and white patients hospitalized with stroke among hospitals participating in a quality-improvement program.
T he burden of stroke is higher in black and Hispanic patients as compared with white patients. 1, 2 Ischemic stroke occurs at an earlier age in black patients, and the prevalence and age-standardized mortality due to ischemic stroke are higher as compared with the general population. 1, [3] [4] [5] Hispanic individuals appear to be at greater risk for stroke as compared with non-Hispanic whites living in the same communities. 6 A few reports have suggested that the quality of care and clinical outcomes for hospitalized stroke patients may vary between different racial/ethnic groups. 5, [7] [8] [9] [10] However, these reports have been limited in size and scope, and their findings have been inconsistent. In addition, few data exist on the trends over time in the quality of care for hospitalized stroke patients of different racial or ethnic backgrounds. It is important to understand stroke treatment patterns and clinical outcomes in minority populations who traditionally have not been well represented in large epide-miological studies or randomized clinical trials. We sought to compare the quality of care in black, white, and Hispanic hospitalized stroke patients over 5 years in a large, national quality-improvement stroke registry and determine whether differences in care and in-hospital outcomes were present.
Clinical Perspective on p 1501
Methods Details of the Get With The Guidelines (GWTG)-Stroke program have been described previously. 9, 11 Data from patients hospitalized with ischemic stroke at a GWTG-Stroke participating hospitals between April 1, 2003, and September 30, 2008 , are included in this analysis. Trained personnel at hospitals were instructed to use GWTG-Stroke to collect data on consecutive patients admitted to the hospital with a principal clinical diagnosis of stroke or transient ischemic attack (TIA). Case ascertainment of admissions for ischemic stroke or TIA was conducted by prospective clinical identification and retrospective identification with International Classification of Diseases (9th revision) discharge codes (433.xx, 434.xx, and 436 for ischemic stroke; 435.xx for TIA), followed by chart review to confirm case eligibility, or a combination of both approaches. To ensure that patients assigned a TIA diagnosis truly had deficits caused by ischemia, hospitals were instructed to include TIA patients only if symptoms were still persistent at the time of hospital arrival, symptoms lasted Ͻ24 hours, and no alternative diagnosis was identified.
Data were collected with the Internet-based Patient Management Tool (Outcome Inc, Cambridge, Mass). Data were coded, deidentified, and transmitted in a secure manner. Data were collected for each hospitalization, including patient demographics, medical history, initial head computed tomography findings, in-hospital treatments and events, discharge treatments and counseling, and discharge destination. The data collection tool supports both concurrent and retrospective data entry; concurrent collection was encouraged as a process improvement goal in each hospital. The data abstraction tool includes links to standard data definitions and coding instructions and predefined logic checks to prevent invalid entries. 9, 11 Training in the use of the tool was provided online and via telephone for all users. Data collected by hospitals were not independently audited by external chart review; however, all sites receive individual data quality reports to promote data completeness and accuracy. GWTG-Stroke also provides annual national reports that examine data quality for every collected data field.
Hospital characteristics, including hospital bed size, academic or nonacademic status, annual volume of stroke discharges, and geographical region, were obtained from the American Hospital Association database. 12 Each participating institution received human research approval from their Institutional Review Board to enroll cases in GWTG-Stroke without requiring individual patient consent. The Duke Clinical Research Institute serves as the data analysis center and has an agreement to analyze the aggregate deidentified data for research purposes.
Using methodology similar to national cardiovascular registries, hospital staff recorded patient race/ethnicity data. Information on race and ethnicity could have been obtained from various sources, including patient self-designation, administrative personnel during the registration process, admitting providers, or nursing intake forms. The data entry tool supports single-race, multi-race, and ethnic classification. From 2003 to September 2005, Hispanic ethnicity was captured as part of a multi-select option that also included racial categories (black, white, Asian, American Indian/Alaska native, and Native Hawaiian/Pacific Islander). Starting in October 2005, a separate data element for Hispanic ethnicity (yes versus no/not documented) was implemented following the recommendations of Census 2000. 13 There were 427 887 ischemic stroke patients admitted to 1188 participating hospitals during the study period. For this study, we restricted analysis to 3 patient groups: non-Hispanic black (referred to as black), non-Hispanic white (referred to as white), or Hispanic regardless of race (referred to as Hispanic). Patients who were classified as Asian, Pacific Islander, mixed race, or any other nonblack or nonwhite categories (nϭ28 490, 6.7%) were therefore excluded. Only 1770 patients (0.41%) were excluded because of missing information on race/ethnicity. An additional 360 patients (0.084%) were excluded because of missing information on sex. The final analysis sample consisted of 397 257 ischemic stroke admissions from 1181 hospitals.
The following 7 predefined, evidence-based performance measures 9, 14 were used to compare the quality of care (QOC) in black, Hispanic, and white patients. These 7 measures were the result of harmonization of performance measurement activities between the American Heart Association, the US Centers for Disease Control and Prevention, and the Joint Commission. Detailed specifications are available for download and review online. 15 Six of the 7 measures were endorsed by the National Quality Forum; the smoking cessation measure was not endorsed solely because of an National Quality Forum decision to release an identical global smoking measure applicable to all inpatient care populations. A summary defect-free care measure 16 (also known as an all-or-none measure) was used as a measure of overall QOC. Defect-free care is defined as the proportion of patients who received all of the interventions for which they were eligible (patients who were not eligible for any of the 7 measures were excluded).
Acute
Acute-term performance measures included the following: intravenous (IV) tissue-type plasminogen activator (tPA) administered to patients who presented to the emergency department within 2 hours after symptom onset and received the drug within 3 hours of symptom onset ("IV tPA Ͻ2 hours"); antithrombotic medication (ie, antiplatelet or anticoagulant agents) administered by end of hospital day 2 ("early antithrombotics"); deep vein thrombosis (DVT) prophylaxis (ie, warfarin, heparin, other anticoagulants, or pneumatic pressure devices) administered by end of hospital day 2 to patients who were nonambulatory at hospital day 2 ("DVT prophylaxis").
Discharge Performance Measures
Discharge performance measures included the following: antithrombotic medication administered at discharge ("antithrombotics"); anticoagulation (ie, warfarin, full-dose heparins, or other anticoagulants) administered at discharge for any atrial fibrillation (paroxysmal, persistent, or permanent) ("anticoag for atrial fibrillation"); lipid-lowering agent administered at discharge to patients with low-density lipoprotein Ͼ100, or those on lipid-lowering agents before admission, or in whom low-density lipoprotein was not measured in the past 30 days ("low-density lipoprotein 100 or not documented"); counseling or medication to help quit smoking provided at or before discharge for patients who are current smokers (any cigarettes in past year; "smoking cessation").
In-Hospital Clinical Outcomes
In-hospital clinical outcomes included the following: the in-hospital case fatality rate for all ischemic stroke admissions, excluding those discharged to hospice ("in-hospital mortality"); the proportion of patients discharged to home versus any other destination ("discharge home"); the median (interquartile range) and mean duration of hospitalization ("length of stay").
Statistical Analysis
Contingency tables were generated to explore the relationship between black, Hispanic, and white race/ethnicity status and other demographic and clinical variables, as well as hospital-level characteristics. Because of prior literature suggesting that there are substantial differences between hospitals that do or do not serve large minority populations, even after accounting for hospital size and teaching status, 7 we created a hospital-level variable expressing the percentage of minority stroke patients (defined as black and Hispanics) treated at each hospital. Similar contingency tables were generated to explore the relationship between race/ethnicity and compliance with the individual and defect-free QOC measures. Pearson 2 test for nominal data and Kruskal-Wallis tests for ordinal and continuous data were used as tests for statistical associations. Statistical significance was defined as PՅ0.01.
The relationship between race/ethnicity (black versus white or Hispanic versus white) and compliance with individual QOC measures, the summary defect-free care measure, and stroke outcomes were then examined using multivariable logistic regression models. Given the large data set, traditional model-building approaches that identify independent predictors based on statistical significance were not used. Instead, the final adjusted models included the following prespecified potential patient-level confounders, which were selected on the basis of published data supporting their association with stroke risk or outcome: age, sex, body mass index, atrial fibrillation, previous stroke/TIA, coronary heart disease or prior myocardial infarction, carotid stenosis, diabetes mellitus, peripheral vascular disease, hypertension, dyslipidemia, and current smoking. In addition, hospital-level characteristics associated with stroke risk or outcome were also included (geographic region, number of beds, academic versus not, annual stroke volume). We also included the hospital-level term for percentage of minority patients treated (spec-ified in quartiles). Inclusion of this model term allows us to more accurately distinguish hospital-level determinants from patient-level determinants of differences in care in the models. Because there were improvements in QOC measure adherence over time, we included adjustments for both calendar time and time in program (specified as years of hospital program participation, which varied between 1 and 6 years). To account for the hierarchical nature of the data, we used hierarchical modeling techniques, including hospital effects, as a random intercept term. 17 Separate hierarchical multivariable logistic regression models were developed for each QOC measure, the summary defect-free care measure, in-hospital mortality, discharge status (home versus other), and length of stay Ͼ4 days versus Յ4 days (median length of stay, 4 days). We developed a hierarchical multivariable logistic regression model to assess how the summary defect-free care measure changed for each race/ethnicity group with increasing time in program for the participating hospitals (years of program participation could vary between 1 and 6 years, and comparisons were made to the baseline period). The model also adjusted for calendar time. In addition, to further evaluate the potential impact of age on our results, we undertook stratified analyses (using 10-year age groups) by racial/ethnic group for the summary defect-free care measure and in-hospital mortality.
All statistical analyses were performed using SAS version 9.1 software (SAS Institute, Cary, NC).The authors had full access to and take full responsibility for the integrity of the data in the study and the accuracy of the data analysis. All authors have read and agree to the manuscript as written.
Results

Patient Characteristics
There were 397 257 ischemic stroke admissions included for analysis. Just over half (52.7%) of the population were women, and the average age was 71.1Ϯ14.5 (SD) years. The race/ethnicity distribution was 79.1% white (nϭ314 102), 16 .0% black (nϭ63 370), and 4.9% Hispanic (nϭ19 785). There were significant differences in demographic and clinical characteristics by racial/ethnic group (Table 1) . Compared with white patients, black and Hispanic patients were substantially younger and less likely to present by ambulance. Black patients were more likely than white patients to have a past medical history of prior stroke/TIA, diabetes mellitus, hypertension, and smoking and were less likely to have a history of atrial fibrillation, heart disease, carotid stenosis, peripheral vascular disease, and dyslipidemia (all PϽ0.0001; Table 1 ). Compared with white patients, Hispanic patients were less likely to have a past medical history of atrial fibrillation, heart disease, and carotid stenosis, but were more likely to have diabetes mellitus.
Hospital Characteristics
The 1181 hospitals included in the analysis were from every state in the continental United States, Puerto Rico, and the District of Columbia (median 14 hospitals per state; range 1 to 119). The median hospital admission volume for ischemic stroke was 203 (interquartile range 59 to 464). There was significant variability across the 3 race/ethnicity groups in hospital characteristics, including bed size, hospital type, volume of stroke discharges, and geographic location ( Table  1) . Black patients were more likely to be treated at larger, academic hospitals than white or Hispanic patients.
When hospitals were stratified into quartiles of the percentage of minority patients treated, significant differences in hospital characteristics between racial groups still remained.
Hospitals that admitted a greater proportion of minority stroke patients were larger (median bed size was 188, 292, 311, and 348 for quartiles 1 through 4 of minority stroke admissions, respectively; PϽ0.0001). The percentage of academic hospitals also increased with greater minority stroke admissions (38.6%, 42.5%, 51.1%, and 59.5% for quartiles 1 through 4, respectively; PϽ0.0001).
QOC Measures
There were statistically significant race/ethnicity differences in unadjusted adherence rates for 4 of 7 QOC measures (DVT prophylaxis, early antithrombotics, lipid-lowering medication prescribed at discharge, and smoking cessation) and the summary defect-free care measure ( Table 2 ). There were no differences in unadjusted rates of use of IV tPA, early antithrombotics, and anticoagulation for atrial fibrillation. When hospitals were stratified by quartile of percentage of minority patients treated, these unadjusted QOC findings did not change (data not shown). When multivariate models were constructed adjusting for patient-level characteristics only, significant and important differences in QOC emerged, predominantly in relation to early antithrombotics, antithrombotics at discharge, and smoking cessation, which, relative to whites, were used less in both black and Hispanic patients ( Table 3) . When comparing differences in QOC between black and white patients, the magnitude of the odds ratios (ORs) and the statistical significance of the IV tPA, DVT prophylaxis, lipid-lowering treatment, and defect-free care measures were amplified when the fully-adjusted model using both hospital-level and patient-level characteristics was generated ( Table 3 ). Black patients had significantly lower adjusted odds compared with white patients of receiving IV thrombolysis (OR, 0.84; 95% confidence interval ͓CI͔, 0.77 to 0.91), DVT prophylaxis (OR, 0.88; 95% CI, 0.83 to 0.92), the discharge use of antithrombotics (OR, 0.88; 95% CI, 0.84 to 0.92), anticoagulation for atrial fibrillation (OR, 0.84; 95% CI, 0.75 to 0.94), smoking cessation (OR, 0.85; 95% CI, 0.79 to 0.91), and cholesterol-lowering medication (OR, 0.91; 95% CI, 0.88 to 0.96), as well as the defect-free measure of QOC (OR, 0.90; 95% CI, 0.88 to 0.93). In contrast, after adjustment for patient-and hospital-level variables, differences between Hispanic and white patients were lessened and remained significant for only antithrombotics at discharge and smoking cessation. In age-stratified analyses of the defect-free care measure, we found that findings were similar with the exception of patients Ͻ50 years of age (online-only Data Supplement).
Clinical Outcomes
There were racial and ethnic differences in unadjusted strokerelated outcomes at discharge (Table 4 ). Black (4.37%) and Hispanic patients (4.90%) were less likely than white patients (6.06%) to die in hospital, and black (47.9%) and Hispanic patients (52.6%) were more likely to be discharged home as compared with whites (44.0%), who were more likely to be discharged to a skilled nursing facility as compared with black and Hispanic patients ( Table 4 ). Black (6.60 days) and Hispanic patients (6.34 days) had a longer length of hospital stay than whites (5.49 days).
In contrast to QOC measure adherence, findings based on multivariable models of clinical outcome that adjusted for only patient-level factors were similar to the fully-adjusted models that also included hospital-level factors ( Table 5 ). After multivariable adjustment for both patient-and hospitallevel characteristics, black patients had lower odds than whites of dying in hospital (OR, 0.90; 95% CI, 0.85 to 0.95) or being discharged home (OR, 0.83; 95% CI, 0.81 to 0.86) and higher odds of exceeding the median length of stay (OR, 1.31; 95% CI, 1.28 to 1.35). By contrast, Hispanic patients had similar in-hospital mortality to whites but greater odds to exceed the median length of stay (OR, 1.16; 95% CI, 1.11 to 1.20) and be discharged home (OR, 1.13; 95% CI, 1.08 to 1.18; Table 5 ). Age-stratified analyses showed the in-hospital mortality comparison of Hispanic versus white patients was consistent across all age groups (online-only Data Supplement). The age-stratified analyses of black versus white patients revealed greater differences in younger (50 to 59 years) and older (80 to 89 years and Ͼ90 years) patients than in other age groups.
Trends in Care and Outcomes
Finally, we explored whether differences in QOC changed in association with the amount of time that hospitals participated in the GWTG-Stroke program (ie, time in program). To explore this, we analyzed changes in the summary defect-free care measure by years of hospital participation in the program within each race/ethnicity group. There were substantial and significant absolute increases in adherence to the defect-free care measure (absolute increase of 30% or more) for all 3 racial/ethnic groups (Figure) . Detailed data on trends over time for each individual measure are available in the onlineonly Data Supplement. When compared with baseline, this substantial improvement persisted after full multivariable adjustment in all 3 racial/ethnic groups (Table 6 ). However, when the rate of improvement in white patients was compared in the fully adjusted models with the rate of improvement for blacks and for Hispanics, there was no evidence of significant interaction with time in program (black versus white, Pϭ0.85; Hispanic versus white, Pϭ0. 16 ).
Discussion
Because of its size, national scope, and duration, the GWTG-Stroke program 14 provides a unique opportunity to analyze presenting characteristics, quality indicators, and in-hospital stroke outcomes as a function of race/ethnicity. In this analysis of nearly 400 000 black, Hispanic, and white patients admitted to Ͻ1100 US hospitals for acute ischemic stroke, we demonstrated that there are important differences in the baseline characteristics, as well as QOC, among different racial/ethnic groups. We found evidence that black patients had lower odds of receiving certain guideline-based stroke interventions relative to white patients-these include shortterm treatments (IV thrombolysis and DVT prophylaxis) and discharge interventions (antithrombotics, anticoagulation for atrial fibrillation, smoking cessation, and cholesterol control), which were reflected in the summary measure of care. Importantly, many of these differences were greater after risk adjustment for patient and hospital characteristics. In contrast, there were limited differences in QOC observed between Hispanic and white ischemic stroke patients. The observation that Hispanic patients receive similar QOC compared with white patients has been previously reported. 18 Although the absolute differences and ORs in individual QOC measures were small, taken together they amount to a consistent pattern of modestly reduced odds for black patients of receiving guideline-recommended care compared with white patients.
We report 2 separate models, 1 adjusted for patient characteristics alone and the other adjusted for patient and hospital characteristics ( Table 3 ). The models adjusted for patient characteristics alone are presented because the Institute of Medicine 19 recommends that these models be used to Statistical tests of differences by race/ethnicity were significant (PϽ0.0001) for all outcomes. IQR indicates interquartile range *In-hospital death and ambulatory status exclude subjects who were transferred to another facility (nϭ11 339). †Length of stay excludes subjects who were transferred in/out or did not have a valid admission or discharge date (nϭ77 041). provide the most appropriate estimates of potential disparities. Although we found no evidence that these differences in care quality had a measurable adverse impact on short-term in-hospital outcomes, this is not unexpected since most of the process measures being assessed are discharge measures. To assess the association between these care differences and clinical outcomes will require analysis of postdischarge (eg, day 90 or 1 year) health status, stroke disability, and mortality. It is important to note that randomized clinical trials of IV tPA have not shown a difference for early outcomes with this therapy or a difference in mortality; therefore, studies that include postdischarge functional status will be required to assess the relationship of this process measure to outcome. Although there were only modest differences in DVT prophylaxis in black patients, these are unlikely to be large enough to result in a difference in overall in-hospital mortality due to pulmonary embolism. The higher odds of being able to ambulate at discharge or be discharged to home after hospitalization for acute ischemic stroke seen in the black and Hispanic patients as compared with white patients in the study may be due to residual confounding by age or other unmeasured factors, rather than differences in hospital QOC. For example, black and Hispanic patients in this study had a higher prevalence of risk factors (especially hypertension and Study population: Nϭ383 502; number of hospitals: Nϭ1075; excluding patients who were not eligible for the defect-free care measure (Nϭ12 917) or who did not have program year information (Nϭ838).
*Adjusted for patient characteristics of age, sex, body mass index, and prior medical history of atrial fibrillation, stroke/transient ischemic attack, coronary heart disease or myocardial infarction, carotid stenosis, diabetes mellitus, peripheral vascular disease, hypertension, dyslipidemia, or smoking.
†Adjusted for hospital characteristics of geographic region, number of beds, annual stroke volume, academic vs not, percentage of minority stroke patients treated, calendar time, time in program, and race vs time in program interaction.
diabetes mellitus) associated with small vessel stroke, which is generally a milder stroke subtype with lower early recurrence rates and better functional recovery. 20 -22 There has been evidence for racial differences in short-and long-term ischemic cardiovascular care documented for black patients in prior studies. [23] [24] [25] Fewer data have been reported for ischemic stroke. In a study of 1837 patients with ischemic strokes from a single state-based registry, black patients with ischemic stroke had lower odds of receiving a door-tocomputed tomography time of less than 25 minutes (OR, 0.13; 95% CI, 0.05 to 0.32), obtain cardiac monitoring (OR, 0.54; 95% CI, 0.29 to 1.03͔), undergo dysphagia screening (OR, 0.69; 95% CI, 0.50 to 0.95), or receive smoking cessation counseling (OR, 0.27; 95% CI, 0.17 to 0.42). 7 In a medical record review from 42 academic medical centers, blacks were one fifth as likely to be administered tPA as whites, a finding that persisted after adjustment (OR, 0.21; 95% CI, 0.06 to 0.68) for sex, severity, and insurance status. 8 In another study in community hospitals, black patients had lower odds of receiving IV tPA (OR, 0.54; 95% CI, 0.31 to 0.95) even after controlling for factors including severity, physician specialty, and location. 26 However, a study in the Michigan Medicare population using retrospective medical record abstraction 27 found no differences in the use of antithrombotics at discharge by race or sex after adjustment for confounders.
Previous studies evaluating racial and ethnic differences in ischemic stroke care have suffered from several important limitations. First, some studies have relied on administrative databases 27 or have included chart abstraction data from only a few hospitals or limited geographical regions or populations. 18 In contrast, our data are from nearly 400 000 ischemic stroke patients from Ͻ1100 hospitals of all types (ie, community, academic, Veterans Administration) and is therefore a more nationally representative sample. In contrast to some of these prior studies, we examined a broad range of guideline-recommended QOC measures, from acute care to secondary prevention.
Although it is possible that observed treatment differences could simply reflect differences in patient characteristics, in this study, racial/ethnic differences persisted or even emerged after controlling for patient-level factors. Controlling for hospital site characteristics further amplified this effect for some QOC measures, particularly among black patients, whereas it had a lesser effect on Hispanic patients. Although certain hospital characteristics such as teaching status and size are commonly thought to play a critical role in QOC differences, our study suggests that this may not be the case. We did not find evidence of poorer performance by sites that admit a disproportionately large number of black or Hispanic patients (the quartile of percentage of minority cases treated) to account for the observed differences. It is of course possible that our findings are the result of other important unmeasured confounders, such as stroke severity, patient preference, or access to a neurologist.
Black patients had lower odds of in-hospital mortality in our study, even after adjustment for age and other factors. Other studies have shown higher rates of risk-adjusted inhospital mortality and ischemic stroke death for black pa-tients, 5, 2829 although some reports of poststroke adjusted mortality that extend beyond hospital discharge have suggested lower rates among black patients 30 and Hispanic patients when compared with whites. 29 Recent data suggest a decline in stroke mortality among all minorities. 31 Hispanic patients in our study had in-hospital mortality similar to white patients. The predilection for small vessel lacunar strokes in black patients has already been mentioned as an explanation for their better long-term prognosis. 20 -22 Studies in Northern Manhattan have shown higher relative rates for lacunar and intracranial atherosclerotic strokes compared with cardioembolic strokes among both Hispanic and black patients compared with whites. 32, 33 Other groups have not found important differences in severity of initial stroke presentation associated with racial or ethnic groups. 34, 35 Because ischemic stroke subtype and stroke severity by National Institutes of Health Stroke Scale score were recorded infrequently in the patient charts, our risk-adjusted model could not account for them.
GWTG-Stroke is a program designed to improve provider knowledge and education for hospitalized stroke patients and to systematically accelerate the use of evidence-based and guideline-recommended therapies. Given the enormous economic burden of stroke and its disproportionate impact on black and Hispanic compared with white patients, 36 it is critical to implement strategies that increase adherence to evidence-based care in this high-risk group. Our study suggests that the implementation of process-of-care intervention programs such as GWTG-Stroke benefits all patients by increasing rates of evidence-based therapies for ischemic stroke. Further study will needed to determine whether equivalent rates of adherence to inpatient measures of guideline-based care among black and Hispanic patients will translate into similar long-term postdischarge outcomes.
This study has several limitations. Because program participation is voluntary, the observed findings may not be representative of hospitals that chose not to participate. However, the GWTG-Stroke database includes hospitals in every state in the United States, and the population in GWTG-Stroke is similar in racial makeup, although with a lower proportion of Hispanic ethnicity when compared with the US population of 75.1% white, 12.3% black, and 12.5% Hispanic as reflected by Census 2000 data. 13 GWTG-Stroke has a similar proportion of female patients and prevalence of stroke risk factors compared with other large stroke registries. 10, 37 Although no formal data reliability studies were performed within this quality-improvement registry, the Michigan Paul Coverdell prototype (which used a very similar data set) found acceptable inter-rater reliability for most of the data elements. 38 In many hospitals, race and ethnicity may have been assigned by administrative personnel during the registration process, by admitting providers, nursing intake forms, or patient self-designation. The attribution of race/ethnicity that is not based on direct self-report may be less reliable. 39 Further, the change to documenting race and ethnicity as separate data elements is relatively recent, and not all hospitals may have the tools in place to do this. Because of variability between hospitals in the process to establish patient ethnicity, it is possible that Hispanic ethnicity is under-reported in this registry. However, prior studies suggest, based on medical records review, that this may occur in Ͻ5% of cases. 40 If so, this misclassification would result in a small underestimation of the magnitude of the Hispanic versus white differences in measure conformity and outcomes. Because GWTG collects only deidentified data that are routinely present in the medical record, socioeconomic data are not collected. This study reports ORs, which should not be interpreted as indicating relative risk.
In conclusion, in this very large, diverse racial/ethnic group of ischemic stroke patients treated at hospitals across the United States over a 6-year period, we found substantial differences in baseline characteristics among black, Hispanic, and white patients, particularly in age of presentation and stroke risk factors. Furthermore, there was evidence of a moderate but consistent reduction in the frequency with which guideline-based care was provided to black as compared with white patients when adjusted for patient and hospital factors. Our findings contrast with some previous reports of substantially poorer QOC for black patients with ischemic stroke; however, our findings are consistent with previous reports showing that Hispanic patients received QOC comparable to that of white patients. Substantial improvements in care quality were observed over time in the GWTG-Stroke program for each racial/ethnic group. Although reassuring, further efforts are needed to improve QOC for ischemic stroke for all patients. Expansion of national strategies for the hospitalbased implementation of quality improvement in ischemic stroke care should be considered, and the planned introduction of stroke measures into the Joint Commission core measure set 15 and Medicare inpatient prospective payment system update 41 should help accelerate these efforts.
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